Who Might Consider It Now, and What FDA Approval Could Change
Galleri is already available by prescription at Rezilir for people willing to pay out of pocket. The more useful question for patients is not simply whether the test exists, but whether it adds enough value for their individual situation.
| The practical bottom line For an asymptomatic adult age 50 or older who is already completing standard cancer screening, understands the limitations of a negative result, and is willing to pursue follow-up after a positive result, Galleri can be considered as an optional additional layer of screening. It should not be used as an “all clear” blood test or as a substitute for proven screening tests. |
What changed at the FDA?
On September 23, 2026, an FDA advisory committee voted favorably on GRAIL’s application for Galleri. The panel supported the test’s safety, effectiveness, and overall benefit-risk profile for the proposed use in adults age 50 and older. That is an important milestone, but it is not the same as FDA approval. The advisory committee makes a recommendation; the FDA still makes the final regulatory decision.
The FDA also focused on an important wording question: does Galleri perform well enough in very early cancers to justify calling it an “early detection” test? That issue matters because Galleri is much better at finding some cancers than others, and it is more sensitive for later-stage cancer than for Stage I disease.
What Galleri does – and what it does not do
Galleri analyzes patterns in cell-free DNA circulating in the blood. It reports either “Cancer Signal Detected” or “No Cancer Signal Detected.” If a signal is found, the test also predicts where in the body the signal most likely originated so that a clinician can direct the next diagnostic steps.
• A positive Galleri result is not a cancer diagnosis. Imaging, endoscopy, biopsy, or other testing may still be needed to confirm whether cancer is present.
• A negative Galleri result does not rule out cancer. The test misses cancers, particularly some very early cancers.
• Galleri should be added to – not substituted for – established screening such as mammography, colorectal cancer screening, indicated low-dose CT lung screening, cervical screening, and individualized prostate screening discussions.
• New or concerning symptoms should be evaluated directly. Galleri is a screening test for people without a current clinical suspicion of cancer; it is not a shortcut around diagnostic evaluation.
How strong is the test?
Galleri’s strongest feature is its very low false-positive rate. In PATHFINDER 2, the version of Galleri submitted to the FDA had 99.85% specificity and a positive predictive value of about 77%. In plain language, a positive result in that study was much more likely to represent a real cancer than many people expect from a broad screening test, although the meaning of any positive result still depends on the population being tested.
The limitation is sensitivity. Galleri does not find every cancer. In an FDA-reviewed analysis from NHS-Galleri, sensitivity was only 13.6% for Stage I cancer, compared with 60.0% for Stage IV cancer. This means a reassuring Galleri result cannot be used to conclude that a person is cancer-free.
The large randomized NHS-Galleri trial also did not meet its prespecified primary endpoint of significantly reducing the combined number of Stage III and IV cancers. There were encouraging secondary findings, including fewer Stage IV cancers, but it has not yet been proven that Galleri screening reduces the chance of dying from cancer. That remains the most important unanswered question.
Who may reasonably consider Galleri now?
Not every healthy adult needs to rush to get this test. The decision is most reasonable when the person understands both the potential value and the remaining uncertainty. Galleri may be worth discussing now if most of the following are true:
• You are age 50 or older. This is the population in the proposed FDA indication and the population in which the major screening studies have been concentrated.
• You are already up to date – or actively becoming up to date – with recommended cancer screening. Galleri works best conceptually as an additional layer, not a replacement.
• You place a high value on looking for cancers that do not currently have routine population screening tests, such as pancreatic, ovarian, liver, or several other serious cancers.
• Your overall cancer concern is higher because of factors such as a strong family history, a known inherited cancer-predisposition syndrome, substantial smoking history, certain occupational or environmental carcinogen exposures, prior therapeutic radiation or elevated biomarkers such as an extremely high covid spike antibody. These factors can raise baseline cancer risk, although Galleri has not yet been proven to improve outcomes specifically in each of these higher-risk groups.
• You are prepared to follow through if the test is positive. The value of screening falls sharply if a person would not be willing or medically able to undergo the diagnostic workup that follows.
• You are comfortable with the current cost and with the possibility that some downstream evaluation could involve deductibles, copays, or coverage review.
Who should be more cautious about ordering it?
Galleri is less compelling if the main goal is reassurance from a single blood draw. It may be a poor fit for someone who wants to use it instead of standard screening, someone with symptoms that already warrant a targeted diagnostic evaluation, or someone who would be unlikely to pursue additional testing after a positive result. An average-risk person under age 50 is also outside the proposed FDA indication and is not the population on which the current approval application is based.
What does Galleri cost today?
Galleri is already commercially available in the United States by prescription even though it does not yet have FDA premarket approval. Most people currently obtain it as a self-pay test. Most commercial health plans and Medicare do not pay for the screening test today. Galleri can be included in your personalized care program, as one more layer in a fuller look at your health. Request an appointment and a care coordinator will walk you through your options.
If the FDA approves Galleri, will insurance cover it?
FDA approval would be a major step toward broader coverage, but it would not create immediate universal payment. FDA approval answers a regulatory question about whether the test is sufficiently safe and effective for its labeled use. Insurers make a separate decision about whether they will pay for it and under what conditions.
Commercial insurance: Coverage would likely expand gradually rather than overnight. Some insurers may adopt coverage after FDA approval, while others may wait for professional-society guidance, additional clinical-outcome data, or a USPSTF recommendation. FDA approval by itself does not require every commercial plan to cover Galleri.
Medicare: The situation is more favorable than it was a few years ago because Congress created a specific Medicare coverage pathway for blood-based multi-cancer early detection tests. That framework is scheduled to begin in 2029. An eligible test must first receive FDA authorization and then meet Medicare’s coverage standard; eligibility is also phased in by age. In other words, even if the FDA approves Galleri soon, patients should not expect automatic nationwide Medicare payment the next day.
Follow-up testing: A positive Galleri result can lead to imaging, specialty consultations, endoscopy, biopsy, or other testing. Whether those services are covered – and what cost sharing applies – depends on the individual plan and the medical justification for the workup. Patients considering Galleri should ask both about the price of the blood test and about how their plan handles diagnostic evaluation after an abnormal screening result.
What would FDA approval actually change for patients?
The biggest immediate change would be confidence that the FDA has completed its formal review and established an approved indication, labeling, and warnings for the test. That would also make it easier for insurers, health systems, and professional organizations to decide how Galleri fits into routine preventive care.
What FDA approval would not do is prove that a negative Galleri test means no cancer, replace established screening, or settle the long-term mortality question. Those limitations would remain important even after approval.
A reasonable way to think about the decision
For a healthy adult over 50 who is already following standard screening recommendations, has access to thoughtful follow-up care, and understands that the test can miss cancer, Galleri can be a reasonable optional add-on today. The case may feel more compelling to people with higher-than-average cancer concern or risk, but the evidence does not yet show that every high-risk group benefits from Galleri screening.
For someone hoping that one blood test can replace mammograms, colon screening, lung CT screening, or other established methods – or provide a definitive “all clear” – Galleri is the wrong tool. Its potential value is broader detection, not comprehensive exclusion of cancer.
The FDA advisory committee vote moves Galleri closer to mainstream use. For patients, however, the most important decision remains personal: whether the possibility of finding an otherwise unscreened cancer is worth the current cost, uncertainty, and possibility of additional testing.
References
2. National Cancer Institute. Questions and Answers about Multi-Cancer Detection Tests.
